Primer Capital, a venture capital biotech fund, made investments in a drug for the treatment of multi-drug-resistant tuberculosis, developed by MT Medicals.
The total amount of the investment round made by Primer Capital, the Russian Ministry of Education and Science and private investors was 44 million rubles. MT Medicals is a resident of SKOLKOVO Foundation’s biomed cluster since 2016.
According to the latest WHO report, in 2015, an estimated 10.4 million new TB cases were reported worldwide. The incidence of multi-drug-resistant tuberculosis is increasing, with almost half of cases reported in Russia, China, and India. For a long time, there were no innovative products and new options for pharmacological treatment of TB, that naturally resulted in a stronger bacterial resistance to existing drugs. The development of new classes of drugs is one of the priorities in the fight against resistant forms of this socially important disease.
MT Medicals developed a highly selective inhibitor of cytochrome P450 enzymes, involved in key vital processes occurring in pathogenic mycobacteria. Meanwhile, none of the drugs currently used for the treatment of tuberculosis is directed towards this target.
The investments will be used for development of the technology for production of a finished dosage form, analytical methods for quality control, and preclinical trials of the drug.